Advertisement
U.S. markets close in 5 minutes
  • S&P 500

    5,259.31
    +10.82 (+0.21%)
     
  • Dow 30

    39,828.99
    +68.91 (+0.17%)
     
  • Nasdaq

    16,394.40
    -5.12 (-0.03%)
     
  • Russell 2000

    2,121.56
    +7.21 (+0.34%)
     
  • Crude Oil

    83.00
    +1.65 (+2.03%)
     
  • Gold

    2,240.10
    +27.40 (+1.24%)
     
  • Silver

    24.98
    +0.23 (+0.92%)
     
  • EUR/USD

    1.0791
    -0.0039 (-0.36%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2622
    -0.0016 (-0.13%)
     
  • USD/JPY

    151.3750
    +0.1290 (+0.09%)
     
  • Bitcoin USD

    70,770.09
    +2,115.81 (+3.08%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

aTyr Pharma to Present at H.C. Wainwright Virtual BioConnect Conference

SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Jill Broadfoot, Chief Financial Officer, will present a corporate overview at the H.C. Wainwright Virtual BioConnect Conference, which is being held from January 10 – 13, 2022.

The presentation will be available on-demand to registered conference attendees starting Monday, January 10, 2022 at 7:00am ET. A copy of the presentation will also be available on the Investor’s section of the company’s website at www.atyrpharma.com and will be available for 90 days following the event.

About aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.

Contact:

Ashlee Dunston

Director, Investor Relations and Corporate Communications

adunston@atyrpharma.com


Advertisement